UNSPSC 51422406: Cloprednol

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H25ClO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SYP56O3GJG, chemically known as 6-chloro-11beta,17alpha, 21-trihydroxypregn-1,4,6-triene-3,20-dione but generally known as cloprednol, which bears US NIH Compound Identifier 21320. European Medicines Agency schedules Cloprednol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06744MIG.

UNSPSC 51422406 Cloprednol is a Commodity code that in recent state and local procurement appears to serve as a catch-all classifier for pharmaceuticals and medical supply procurements that do not map neatly to more specific drug or device codes. The recent opportunities tagged under this code show minimal relevance to cloprednol itself — a corticosteroid — and instead reflect broader pharmaceutical and health-system procurement activity. State and local health departments, county health systems, and state health and human services commissions are the primary issuing bodies, soliciting naloxone (opioid reversal medication), drug deactivation systems, and direct-to-manufacturer prescription fulfillment capabilities. The work ranges from tactical product purchases with defined unit volumes and delivery schedules to exploratory requests for information about pharmaceutical supply-chain restructuring and cost management.

Recent activity is concentrated in Florida and Texas. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with an electronic bid deadline of July 26, 2023, and a two-year initial contract term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to evaluate direct contracting between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements; this RFI functions as exploratory market intelligence rather than a formal competitive solicitation with binding timelines or budget commitments. The code shows little evidence of sustained or widespread activity — the two opportunities represent distinct procurement tracks (product supply versus supply-chain innovation) with no indication of repeat buyers or geographic concentration beyond these two entries.